Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineOverall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form